Amarin Corporation plc (AMRN) -Nasdaq The price closed above the 100-Day moving avarage and the $6.34 resistance line, while the indicators still positive and wants more upside. The next important line to breakout is the Brown downtrend line around $6.70 that will make the weekly resistance line at $7.56 as the next target. Expect some technical correction […]
PGNX – A Hidden Bullish Divergence
Progenics Pharmaceuticals, Inc. (PGNX) -Nasdaq On June 11, 2013 Progenics and Salix (partner) announced an FDA Advisory Committee (AdCom) is scheduled to review Relistor sNDA for opioid-induced constipation(OIC) in patients with chronic pain. On July 27, 2012 Salix (SLXP) and Progenics received CRL from the FDA regarding the RELISTOR sNDA. But Slaix filed a formal appeal […]
IBB – Technical Commentary
iShares Nasdaq Biotechnology (IBB) – Nasdaq The best indicators for our biotech portfolio are the biotechnology indices IBB, NBI, XBI or XLV. After publishing “IBB – Biotechnology Index at All Times High“, we wanted to maintain our focus on the IBB. In today’s video “IBB – Market Activity” Tony noted a large bearish bet or hedge […]
ASTX – Breaking out of the Downtrend Channel
Astex Pharmaceuticals, Inc. (ASTX) -Nasdaq ASTX had an epic run that started at the end of February from the low of $2.94, just after two months of price consolidation, and reached a six year’s high of $6.95 on April 30, 2012. From that point, the stock started a deep technical correction, trading in a downtrend channel […]
BMY – In A Consolidation Mode
Bristol-Myers Squibb Company (NYSE: BMY) BMY had an amazing run ahead of ASCO-2013 that left many well-planned traders very happy. The stock found strong support near the 50-Day Moving Average around $39.50 where many traders(ourselves included) started initial positions. The stock had a great run into the ASCO abstracts release on May 15th, moving roughly […]
SRPT – Sarepta – Is It The Time For A New High?
Sarepta Therapeutics, Inc – Nasdaq(SRPT) Sarepta is one of the most followed tickers in twitterville with a real bulls/bears debate. It has strong moms’ advocacy groups fighting full strength to get the drug Eteplirsen an AA (Accelerated Approval) and as fast as they can to the market. For some kids, every day counts as they are […]
IBB – Biotechnology Index at All Times High
Nasdaq Biotechnology Index Fund ETF (IBB) The best indicator for our biotech portfolio are the biotechnology indexes like IBB, NBI, XBI or XLV. Since we already published “The IBB and SPX In The Decision Zone“, we will maintain our focus on the IBB. By looking at the IBB daily chart, we get the whole picture […]
SRPT – A Quick Look At The Chart
Sarepta Therapeutics, Inc – Nasdaq(SRPT) Quick update: A big drop in SRPT today leaving the traders with speculation that there could be a leak about the decision to file for accelerated approval(AA) or not yet. For now, let’s take a look at the chart & check the technical standpoint. Daily Chart The price has been trading […]
DCTH – Soaring Ahead of The Upcoming Advisory Committee
Delcath Systems, Inc. (DCTH) -Nasdaq DCTH has been on our watch list for a while, looking for an entry point. we kept following out the stock performance at the forum and stated a position at $1.63 just after the price found a support around the 200-day Moving Average, also added more shares to the position at […]
XNPT – It’s Time to Join The Run To The Ph-3 Resutls
Xenoport, Inc. (XNPT) -Nasdaq Lately, the reals runner were those with pending clinical trial data, where we saw TSRX and ZIOP’s share price move much more than the PDUFA runners. After TSRX and ZIOP(data from both are expected this week), we want to have a look at XNPT, which is expected to release Phase 3 […]
SGMO – Is it The Time For a Correction
Sangamo Biosciences Inc. (SGMO) -Nasdaq Within three months the share price of SGMO doubled, soaring from the $5.50 area and reaching a new 5 years high of $11.24, getting a boost from the hype around the clinical data that investors were anticipating to be presented at CROI 2013. Jason had a thorough report “SGMO: Sangamo […]
ZIOP – Preparing for an Explosive Move
ZIOPHARM Oncology, Inc. (ZIOP)-Nasdaq Since November 11, 2012 ZIOP was trading in a horizontal channel, the upper resistance line at $4.81 and the lower support line at $4.01, till February 12, 2013, the day ZIOP announced that the Phase 3 (PICASSO 3) trial of palifosfamide (ZIO-201) in first-line metastatic soft tissue sarcoma has reached its […]
DEPO – Action Ahead Of The AdCom
DepoMed Inc. (DEPO) -Nasdaq Serada is an investigational formulation of gabapentin, an FDA-approved immediate release pharmaceutical for the treatment of partial epilepsy and management of postherpetic neuralgia (PHN). Recently published studies suggest the potential application of gabapentin for the treatment of menopausal hot flashes. Based on these findings, Depomed has secured exclusive rights to develop […]
SRPT – Preparing For The Next Move
Sarepta Therapeutics, Inc. (SRPT)-Nasdaq Sarepta is a biotech company under the spotlights since early October 2012, after presenting strong Phase IIb results for the compound Eteplirsen in the treatment of Duchenne Muscular Dystrophy. On October 3rd, 2012, SRPT jumped an unbelievable 199.7% by the closing bell, but as with every huge spike, profit taking started […]
ARRY – Is It Ready For The Next Move
Array BioPharma, Inc. (ARRY)-Nasdaq As a technical analyst I’m looking for patterns and throughout the years I’ve found that stock patterns show that more often than not history repeats itself. Looking at the one year ARRY chart, we can see the uptrend started January 2012, stopped for a while after the February 10th, 2012 price […]
The IBB and SPX In The Decision Zone
In my previous report “IBB – A Closer Look at the Market’s Direction” I tried to find out if the markets bottomed out after the technical correction in the indices $IBB and $SPX, as both reached a support area, and the price found a support line around the Fibonacci 61.8% . Is it the bottom ? […]
ONTY – Preparing For The Next Move
Oncothyreon Inc (ONTY)-Nasdaq Oncothyreon’s getting a lot of attention ahead of its near term catalyst set for Q1 2013 with the final analysis of its pivotal START trial. Results expected during January to February 2013. Daily chart On 11/7/2012, along with the negative sentiment in the overall US markets, and especially in the Biotech sector, […]
CLDX – A Positive Divergence Case
Celldex Therapeutics, Inc. (CLDX)-Nasdaq CLDX’s chart is one of a kind and very easy to understand even by a novice chart technician. It has been repeating the same moves, creating a pattern that makes it easy to predict, using a historical resistance & support lines to find the points of the reversals. Starting in June […]
FOLD – Getting Ready For The New Uptrend
Amicus Therapeutics, Inc. (NASDAQ: FOLD) With FOLD on the move again, we wanted to look at how the stock is performing from a technical perspective , especially after Patrick’s report “FOLD – Bullish on Amicus Therapeutics” which highlighted the upcoming catalysts for this company. In particular, the top-line data from their Phase 3 study of […]
IBB – A Closer Look at the Market’s Direction
In my previous report “IBB – Nasdaq Biotechnology Index – Reaching a Critical Point ” I tried to find out if the technical correction in the index $IBB reached a support area, and the price found a support line around the Fibonacci 61.8 or the weekly support line at 126.90 points. Today the price reached […]
